Clinical Nuclear Medicine

Skip Navigation LinksHome > March 2014 - Volume 39 - Issue 3 > Avastin Scintigraphy in Surveillance of Bevacizumab Treatmen...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0000000000000329
Interesting Images

Avastin Scintigraphy in Surveillance of Bevacizumab Treatment in a Patient With Neurofibromatosis Type 2: A Case Report

Versleijen, Michelle W.J. MD*; Verbist, Berit M. MD; Mulder, Jef J.S. MD; de Geus-Oei, Lioe-Fee MD*; van Herpen, Carla M.L. MD§

Collapse Box


Abstract: A patient with neurofibromatosis type 2 (bilateral vestibular schwannomas) was treated with bevacizumab (anti-vascular endothelial growth factor [VEFG] monoclonal antibody). The left-sided tumor showed intense uptake on pretreatment 111In-bevacizumab scintigraphy, indicating VEGF production in the tumor, and no uptake 4 weeks later, demonstrating effective binding of nonradiolabeled bevacizumab to the VEGF produced in the tumor. The right-sided tumor showed no tracer uptake at any time point. Significant tumor volume reduction (assessed with MRI) and hearing improvement were observed on the left side. 111In-bevacizumab scintigraphy may be a promising upfront patient selection tool to identify patients who may benefit from expensive bevacizumab treatment.

© 2014 by Lippincott Williams & Wilkins


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.